Fierce Pharma
healthCenter
<a href="https://www.fiercepharma.com/marketing/fda-dings-alar-over-extremely-concerning-ketamine-claims" hreflang="en">FDA dings Alar over ‘extremely concerning’ ketamine claims</a>translating…
The FDA sent Alar Pharmaceuticals an untitled letter after finding fault with the company’s exhibit booth display and brochure at a recent conference.
Keywords#Alar#fda#health